港股异动 | 百奥赛图-B(02315)午后涨超10% 与齐鲁制药签署全人纳米抗体分子非排他授权合作协议

智通财经09-08

智通财经APP获悉，百奥赛图-B(02315)午后涨超10%，截至发稿，涨8.71%，报63港元，成交额1.29亿港元。消息面上，据百奥赛图官微消息，公司宣布近期与齐鲁制药签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano®纳米抗体平台产生。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2665934210?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-08 13:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665934210","market":"fut","top_or_hot":-1,"title":"港股异动 | 百奥赛图-B(02315)午后涨超10% 与齐鲁制药签署全人纳米抗体分子非排他授权合作协议","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)午后涨超10%，截至发稿，涨8.71%，报63港元，成交额1.29亿港元。消息面上，据百奥赛图官微消息，公司宣布近期与齐鲁制药签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano®纳米抗体平台产生。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1493233.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百奥赛图-B(02315)午后涨超10% 与齐鲁制药签署全人纳米抗体分子非排他授权合作协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百奥赛图-B(02315)午后涨超10% 与齐鲁制药签署全人纳米抗体分子非排他授权合作协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-08 13:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1493233.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)午后涨超10%，截至发稿，涨8.71%，报63港元，成交额1.29亿港元。消息面上，据百奥赛图官微消息，公司宣布近期与齐鲁制药签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano®纳米抗体平台产生。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1493233.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688796","symbol_name":"百奥赛图","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1493233.html","article_id":"2665934210","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665934210","pubTimestamp":1788846789,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，百奥赛图-B午后涨超10%，截至发稿，涨8.71%，报63港元，成交额1.29亿港元。消息面上，据百奥赛图官微消息，公司宣布近期与齐鲁制药签署全人纳米抗体分子非排他授权合作协议。本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano纳米抗体平台产生。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688796":"百奥赛图","BK1574":"生物医药B类股","01477":"欧康维视生物-B","BK0216":"研究试验","KCAI":"KraneShares China Alpha Index ETF","BK1191":"制药","02315":"百奥赛图-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技"},"translate_title":"Hong Kong Stocks in Focus | Biocytography-B (02315) surges over 10% in the afternoon after signing a non-exclusive licensing cooperation agreement with Qilu Pharmaceutical for a fully human nanobody molecule.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1.5,"VXUS":1.5,"KCAI":1.5,"02315":1.5,"01477":1.5},"content_text":"智通财经APP获悉，百奥赛图-B(02315)午后涨超10%，截至发稿，涨8.71%，报63港元，成交额1.29亿港元。消息面上，据百奥赛图官微消息，公司宣布近期与齐鲁制药签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。本次合作涉及的纳米抗体分子由百奥赛图自主研发的RenNano®纳米抗体平台产生。RenNano®平台可用于发现具有良好特异性、亲和力和开发潜力的全人纳米抗体分子，并可为单域抗体、双/多特异性抗体、抗体偶联药物及其他创新形式的设计与开发提供分子基础。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665934210","isCrawlerRequest":true}